Your pre-publication copy is now available.
Just a couple of years ago Sanofi’s fedratinib – a Jakafi competitor — was dead in the water. Its Phase 3 clinical trial was suspended by the FDA. The trial was aborted by its sponsor, Sanofi.
This year, in the hands of Celgene, the drug was revived as inrebic and approved by the FDA. Last month Bristol-Myers Squibb acquired Celgene for $74 Billion.
It’s part of the MPN Gold Rush that transformed our rare disease into rock star status with Incyte’s Jakafi rocketing to $1.4 billion in MF annual sales. And it complicates our MPN lives.
It all started with a tube of skin cream…
That’s the lead story of the January 2020 MPNforum…PLUS Good news as gene editing closes in on blood cancers. AND a fresh update of the List of Patient-recommended Hematologists.
Your MPNforum pre-publication copy is available now at https://mpnforum.com/january-2020/
You have the weekend to look it over before publication so do please shoot any corrections or comments to us: ourMPNforum@gmail.com